Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation between Transient Elastography (Fibroscan®) and Ultrasonographic and Computed Tomographic Grading in Pediatric Nonalcoholic Steatohepatitis

  • Lee, Ji Eun (Department of Pediatrics, Konyang University Hospital, Konyang University College of Medicine) ;
  • Ko, Kyung Ok (Department of Pediatrics, Konyang University Hospital, Konyang University College of Medicine) ;
  • Lim, Jae Woo (Department of Pediatrics, Konyang University Hospital, Konyang University College of Medicine) ;
  • Cheon, Eun Jung (Department of Pediatrics, Konyang University Hospital, Konyang University College of Medicine) ;
  • Song, Young Hwa (Department of Pediatrics, Konyang University Hospital, Konyang University College of Medicine) ;
  • Yoon, Jung Min (Department of Pediatrics, Konyang University Hospital, Konyang University College of Medicine)
  • Received : 2021.09.05
  • Accepted : 2022.04.05
  • Published : 2022.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to examine the advantages and usefulness of transient elastography (Fibroscan®) in diagnosing non-alcoholic steatohepatitis in children and adolescents compared to those of abdominal computed tomography and liver ultrasonography. Methods: Forty-six children and adolescent participants aged between 6 and 16 years who underwent transient elastography (Fibroscan®) as well as liver ultrasonography or abdominal computed tomography were included. Thirty-nine participants underwent liver ultrasonography and 11 underwent computed tomography. The physical measurements, blood test results, presence of metabolic syndrome, and the degree of liver steatosis and liver fibrosis were analyzed, and their correlations with transient elastography (Fibroscan®), abdominal computed tomography, and liver ultrasonography, as well as the correlations between examinations, were analyzed. Results: Thirty-six participants (78.3%) were boys, and the mean age was 12.29±2.57 years, with a mean body mass index of 27.88±4.28. In the 46 participants, the mean values for aspartate aminotransferase, alanine aminotransferase, and total bilirubin were 89.87±118.69 IU/L, 138.54±141.79 IU/L, and 0.77±0.61 mg/dL, respectively. Although transient elastography (Fibroscan®) and abdominal computed tomography grading had a statistically significant positive correlation with aspartate aminotransferase and alanine aminotransferase values, the correlations between the results of grading performed by transient elastography (Fibroscan®), abdominal computed tomography, and liver ultrasonography were not statistically. Conclusion: We confirmed that each examination was correlated with the results of some blood tests, suggesting the usefulness and possibility of diagnosis and treatment of steatohepatitis mediated by transient elastography (Fibroscan®) in the department of pediatrics.

Keywords

Acknowledgement

This research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (NRF-2017R1C1B5076076).

References

  1. Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389-95. https://doi.org/10.1038/ajg.2010.275
  2. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009;104:1953-60. https://doi.org/10.1038/ajg.2009.238
  3. Mouzaki M, Trout AT, Arce-Clachar AC, Bramlage K, Kuhnell P, Dillman JR, et al. Assessment of nonalcoholic fatty liver disease progression in children using magnetic resonance imaging. J Pediatr 2018;201:86-92. https://doi.org/10.1016/j.jpeds.2018.05.024
  4. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002-9. https://doi.org/10.1007/BF02208670
  5. Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C, et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2007;61:877-83. https://doi.org/10.1038/sj.ejcn.1602588
  6. Kim SU, Han KH, Park JY, Ahn SH, Chung MJ, Chon CY, et al. Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. Liver Int 2009;29:810-5. https://doi.org/10.1111/j.1478-3231.2008.01894.x
  7. de Ledinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007;45:443-50. https://doi.org/10.1097/MPG.0b013e31812e56ff
  8. Zeng J, Zhang X, Sun C, Pan Q, Lu WY, Chen Q, et al. Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years. BMC Pediatr 2019;19:129. https://doi.org/10.1186/s12887-019-1487-6
  9. Goyal R, Mallick SR, Mahanta M, Kedia S, Shalimar, Dhingra R, et al. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B. J Gastroenterol Hepatol 2013;28:1738-45. https://doi.org/10.1111/jgh.12318
  10. Kim SU, Jang HW, Cheong JY, Kim JK, Lee MH, Kim DJ, et al. The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study. J Gastroenterol Hepatol 2011;26:171-8. https://doi.org/10.1111/j.1440-1746.2010.06385.x
  11. Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011;54:64-71. https://doi.org/10.1016/j.jhep.2010.06.022
  12. Kwon YD, Ko KO, Lim JW, Cheon EJ, Song YH, Yoon JM. Usefulness of transient elastography for non-invasive diagnosis of liver fibrosis in pediatric non-alcoholic steatohepatitis. J Korean Med Sci 2019;34:e165. https://doi.org/10.3346/jkms.2019.34.e165
  13. Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485-9. https://doi.org/10.1016/j.dld.2006.03.021
  14. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006;239:105-12. https://doi.org/10.1148/radiol.2391050361
  15. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42:272-82. https://doi.org/10.1016/j.dld.2010.01.021
  16. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012;32:902-10. https://doi.org/10.1111/j.1478-3231.2012.02781.x
  17. Kim SH, Lee JM, Kim JH, Kim KG, Han JK, Lee KH, et al. Appropriateness of a donor liver with respect to macrosteatosis: application of artificial neural networks to US images--initial experience. Radiology 2005;234:793-803. https://doi.org/10.1148/radiol.2343040142
  18. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082-90. https://doi.org/10.1002/hep.24452
  19. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009;51:1061-7. https://doi.org/10.1016/j.jhep.2009.09.001
  20. Iwasaki M, Takada Y, Hayashi M, Minamiguchi S, Haga H, Maetani Y, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004;78:1501-5. https://doi.org/10.1097/01.TP.0000140499.23683.0D
  21. Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015;7:769-76. https://doi.org/10.4254/wjh.v7.i5.769
  22. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137:727-9. https://doi.org/10.1148/radiology.137.3.6934563
  23. Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol 2019;13:447-61. https://doi.org/10.1080/17474124.2019.1595589
  24. Mencin AA, Lavine JE. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2011;14:151-7.
  25. Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13:397-402. https://doi.org/10.1097/MCO.0b013e32833aae84
  26. Lindback SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, et al. Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr 2010;57:85-140. https://doi.org/10.1016/j.yapd.2010.08.006
  27. Kang Y, Park S, Kim S, Koh H. Estimated prevalence of adolescents with nonalcoholic fatty liver disease in Korea. J Korean Med Sci 2018;33:e109. https://doi.org/10.3346/jkms.2018.33.e109
  28. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-44. https://doi.org/10.1136/gut.2008.171280
  29. Ko JS, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009;54:2225-30. Erratum in: Dig Dis Sci 2009;54:2771. https://doi.org/10.1007/s10620-009-0949-3
  30. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003;143:500-5. https://doi.org/10.1067/S0022-3476(03)00325-1
  31. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. https://doi.org/10.1002/hep.23784
  32. Caserta CA, Pendino GM, Amante A, Vacalebre C, Fiorillo MT, Surace P, et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol 2010;171:1195-202. https://doi.org/10.1093/aje/kwq073
  33. Yang HR. Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease. Korean J Pediatr 2013;56:45-51. https://doi.org/10.3345/kjp.2013.56.2.45
  34. Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol 2010;22:643-50. https://doi.org/10.1097/meg.0b013e32832ca0cb
  35. Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020;9:1005. https://doi.org/10.3390/cells9041005
  36. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1264-81.e4. https://doi.org/10.1053/j.gastro.2018.12.036
  37. Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:274-82. https://doi.org/10.1038/nrgastro.2018.10
  38. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362-73. Erratum in: Lancet Gastroenterol Hepatol 2020;5:e3. https://doi.org/10.1016/s2468-1253(19)30383-8
  39. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008;7:350-7. https://doi.org/10.1016/S1665-2681(19)31836-8
  40. Serai SD, Panganiban J, Dhyani M, Degnan AJ, Anupindi SA. Imaging modalities in pediatric NAFLD. Clin Liver Dis (Hoboken) 2021;17:200-8. https://doi.org/10.1002/cld.994
  41. Trout AT, Dillman JR, Xanthakos S, Kohli R, Sprague G, Serai S, et al. Prospective assessment of correlation between US acoustic radiation force impulse and MR elastography in a pediatric population: dispersion of US shear-wave speed measurement matters. Radiology 2016;281:544-52. https://doi.org/10.1148/radiol.2016152797
  42. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017;66:1486-501. https://doi.org/10.1002/hep.29302
  43. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-20. Erratum in: Ann Intern Med 2013;159:308. https://doi.org/10.7326/0003-4819-158-11-201306040-00005
  44. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7. https://doi.org/10.1136/gut.2007.146019
  45. Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013;19:1219-29 https://doi.org/10.3748/wjg.v19.i8.1219